Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. But the German drugmaker failed to crack the top three of the full table, which the same three companies occupied again.
PatientView generated the rankings, surveying 502 rare disease patient groups about their views on individual companies and pharma in general from December 2025 to March 2026. Ranking drugmakers that they were familiar with, patient groups catapulted (PDF) Boehringer up another four places on the leaderboard, adding to the seven places it gained (PDF) in the previous survey.
Despite the back-to-back jumps, Boehringer again fell outside of the top three. As in the previous survey, Sobi, Roche and BioMarin took the top three spots, in that order. The number of patient groups familiar with Sobi rose from 213 to 225 between the two surveys.
Boehringer occupied a leadership position in the three other cuts of the PatientView data. Asked to rate companies they work with, patient groups again put Sobi and Roche in the top two spots, but Boehringer took third place at the expense of BioMarin. Boehringer was second among Big Pharma companies that patient groups were familiar with or work with, trailing Roche on both rankings.
